Allostery Investments’s Tourmaline Bio TRML Stock Holding History

Allostery Investments’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,356	Closed	-$150K	–	19
2025 Q2	$150K	Buy	+9,356	New	+$152K	1.91%	15

Other funds holding TRML

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Allostery Investments's TRML Position: Q3 2025 in Review

Allostery Investments sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 9,356 shares — an estimated $150K sold.

Allostery Investments first reported a position in TRML in Q2 2025 and held it in 1 quarter. The position peaked at $150K in Q2 2025. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

Allostery Investments reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
Allostery Investments sold 9,356 Tourmaline Bio shares in Q3 2025, an estimated $150K.
Allostery Investments first reported a position in Tourmaline Bio in Q2 2025 and held it in 1 quarter.
Allostery Investments's Tourmaline Bio position peaked at $150K in Q2 2025.
134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Allostery Investments's 13F filing for Q3 2025.